

Ralf Thomas elected Chairman of the Supervisory Board of Siemens Healthineers AG

On November 26, 2019, the Supervisory Board of Siemens Healthineers AG unanimously elected Ralf Thomas, 58, as its new Chairman, effective December 1, 2019. Ralf Thomas will succeed Michael Sen, 51, who resigned from his position as Chairman of the Supervisory Board, effective the close of November 30, 2019. Michael Sen is the co-CEO of Siemens' Gas and Power Operating Company and the designated CEO of Siemens Energy AG, which is to become a publicly listed company in September 2020.

"I wish to thank the Supervisory Board for the trust they have placed in me, and I am looking forward to this interesting new challenge. I especially want to thank Michael Sen for his tremendous commitment to Siemens Healthineers. He has been instrumental in developing the medical technology business of Siemens AG for many years – first as CFO and ultimately as Supervisory Board Chairman – and he particularly deserves a great deal of credit for his work on the IPO of Siemens Healthineers. Siemens Healthineers AG generates significant value for its shareholders and therefore for Siemens AG, too. With the second phase of its medium-term strategy, Strategy 2025, which has just begun, the company is further expanding its technology leadership and entering attractive fields of business in adjacent markets," said Thomas after his election as Supervisory Board Chairman.

"Congratulations to Ralf Thomas for being elected the new Chairman of the Supervisory Board of Siemens Healthineers AG. Following the IPO, Siemens Healthineers has successfully completed the first phase of its Strategy 2025. The latest business figures and the development in the share price underline that the company has reached a higher level of performance and is making excellent progress. This is a good time to hand over responsibility as Chairman of the Supervisory Board of Siemens Healthineers. As the future CEO of Siemens Energy, I am now putting all my strength into the upcoming spin-off and the successful future of that exciting company," said Michael Sen, outgoing Chairman of the Supervisory Board of Siemens Healthineers AG.

Ralf Thomas has been the CFO of Siemens AG since 2013. In addition, he has been a member of the Supervisory Board of Siemens Healthineers AG and the Chairman of its Audit Committee since March 2018. The medical technology company listed shares on the Frankfurt Stock Exchange on March 16, 2018. Siemens AG holds an 85 percent equity interest in Siemens Healthineers AG.

This press release as well as pictures are available at:

<https://www.siemens-healthineers.com/press-room/press-releases/pr-ralf-thomas.html>

Contact for journalists

Matthias Kraemer

Phone: +49 9131 84-3383; E-Mail: matthias.kraemer@siemens-healthineers.com

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion. Further information is available at www.siemens-healthineers.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. The information contained in this document is provided as of the date of its publication and is subject to change without notice.